- Home
- RYDE vs CYCN Comparison
RYDE vs CYCN Comparison
Compare RYDE & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYDE
- CYCN
- Stock Information
- Founded
- RYDE 2014
- CYCN 2018
- Country
- RYDE Singapore
- CYCN United States
- Employees
- RYDE N/A
- CYCN N/A
- Industry
- RYDE
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- RYDE
- CYCN Health Care
- Exchange
- RYDE NYSE
- CYCN Nasdaq
- Market Cap
- RYDE 5.2M
- CYCN 6.5M
- IPO Year
- RYDE 2024
- CYCN N/A
- Fundamental
- Price
- RYDE $0.31
- CYCN $3.07
- Analyst Decision
- RYDE
- CYCN
- Analyst Count
- RYDE 0
- CYCN 0
- Target Price
- RYDE N/A
- CYCN N/A
- AVG Volume (30 Days)
- RYDE 29.3M
- CYCN 20.6K
- Earning Date
- RYDE 05-02-2025
- CYCN 08-06-2025
- Dividend Yield
- RYDE N/A
- CYCN N/A
- EPS Growth
- RYDE N/A
- CYCN N/A
- EPS
- RYDE N/A
- CYCN N/A
- Revenue
- RYDE $6,557,978.00
- CYCN $2,081,000.00
- Revenue This Year
- RYDE $21.13
- CYCN N/A
- Revenue Next Year
- RYDE $13.43
- CYCN N/A
- P/E Ratio
- RYDE N/A
- CYCN N/A
- Revenue Growth
- RYDE 3.27
- CYCN N/A
- 52 Week Low
- RYDE $0.16
- CYCN $1.27
- 52 Week High
- RYDE $22.49
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- RYDE N/A
- CYCN 45.97
- Support Level
- RYDE N/A
- CYCN $3.02
- Resistance Level
- RYDE N/A
- CYCN $3.22
- Average True Range (ATR)
- RYDE 0.00
- CYCN 0.23
- MACD
- RYDE 0.00
- CYCN -0.02
- Stochastic Oscillator
- RYDE 0.00
- CYCN 39.22
About RYDE RYDE GROUP LTD
Ryde Group Ltd operates a technology platform that provides a range of ride-hailing, carpooling and delivery focused offerings in Singapore. The company operates in twos segments namely Mobility provides on-demand and scheduled carpooling and ride-hailing services, matching riders to its driver partners; and Quick Commerce provides on-demand, scheduled, and multi-stop parcel delivery services.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.